• Non-small cell lung cancer (NSCLC)
• Breast cancer

Vinozest 50mg Injection works by inhibiting the microtubule structures within the cell. Microtubule structures help cancer cells to divide and multiply. Inhibition of these structures slows the growth and multiplication of cancer cells.

Inform your doctor about any prescribed medications, over-the-counter medications, nutritional or vitamin supplements and herbal products that you are taking or have taken before the treatment. Certain medications tends to interact with Vinozest 50mg Injection and can cause undesirable side effects. 

• Keep Vinozest 50mg Injection out of sight and reach of children.
• Store in a refrigerator (2°C to 8°C).

This medication is administered into a vein by your healthcare provider. The dose and duration is decided by your physician depending on the condition. 

Side effects are unwanted symptoms caused by medicines. Even though all medicines cause side effects, not everyone gets them.

Serious:

• Severe allergic reactions (rash, difficulty in breathing, swelling of eyelids, lips, face, or throat)
• Severe chest pain
• Severe low blood pressure (severe dizziness, lightheadedness when you stand up)
• Severe constipation with abdominal pain
• Major infection (cough, fever, chills)

Common:

• Nausea, vomiting
• Low blood cell counts, weakness
• Hair loss
• Swelling or sores in the throat or mouth
• Injection site reactions (redness, burning pain, vein discoloration)
• Pain in the jaws, joints, and muscles
• Tiredness
• Diarrhea

It is suggested that women should use effective birth control for at least three months before starting and during treatment with Vinozest 50mg Injection. Male patients are advised to use effective contraception during therapy and three months after treatment to avoid fathering children.  Before receiving Vinozest 50mg Injection treatment, male patients should get advice on sperm conservation. Your doctor may take regular blood tests to monitor your blood cell count, platelet count, and liver function.

1. Pierre Fabre Limited, Electronic medicines compendium (EMC), [Revised on Nov 2022] [ Accessed on 1st Dec 2022], https://www.medicines.org.uk/emc/files/pil.3912.pdf
2. Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, Cytotoxic agents, 12th edition, 2011, 1706.
3. KD Tripathi, Essentials of Medical Pharmacology, Anticancer drugs, 7th edition, 2013, 865.
4. Pierre Fabre Medicament, US Food and Drug administration, [Revised on Jan 2022] [ Accessed on 1st Dec 2022], https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020388s037lbl.pdf
5. Anna Capasso; Vinorelbine in Cancer therapy; Cancer Drug Targets; Published on July 2012; Accessed on 01/12/2022; https://pubmed.ncbi.nlm.nih.gov/22594474/
6. Ying-Chun Xu et al; A systematic review of vinorelbine for the treatment of breast cancer; The Breast Journal; Published on April 2013; Accessed on 01/12/2022; https://pubmed.ncbi.nlm.nih.gov/23320984/